Geron Corporation operates as a biopharmaceutical company in the United States. It develops and commercializes three groups of products: therapeutic products for oncology that target telomerase; pharmaceuticals that activate telomerase in tissues impacted by senescence, injury or degenerative disease; and cell-based therapies derived from its human embryonic stem cell platform for applications in various diseases. The company develops anti-cancer therapies based on telomerase inhibitors, telomerase therapeutic vaccines, as well as through its licensee, telomerase-based oncolytic viruses. It also develops drugs that activate telomerase for cell repair/function in senescent tissues...